Lupin Ltd’s Goa manufacturing facility underwent a US FDA inspection from 10 to 21 Nov 2025 and received a Form-483 citing seven observations; the company will address the findings and respond within the stipulated timeframe.
Source: Lupin Press Release (NSE Exchange Fillings) | Published on Nov 21, 2025
Disclaimer: This content has been published for informational purposes only. Bajaj Broking is not affiliated with, nor does it endorse or assume any responsibility for, the source material. Readers are advised to consult the original publication for complete and accurate context.
As quoted in the press release of Lupin (NSE Exchange Filings), the company's board notified stock exchanges that the manufacturing facility located in Goa, India, was inspected by the U.S. Food and Drug Administration (US FDA) from November 10 through 21, 2025. At the conclusion of the inspection, the US FDA issued a Form 483 with seven observations.
It was confirmed by the company that it will reply to the US FDA with a response within its timeline, and maintain a commitment to compliance with current Good Manufacturing Practice (cGMP) for all of its units.
Also read: Shilpa Medicare Unit IV Receives US FDA Form 483 with Eight Findings
Inspection period: 10–21 November 2025.
Facility: Goa, India manufacturing site.
Outcome: Form 483 with seven observations issued by US FDA.
Company commitment: To address observations and respond within required timeframe.
CGMP standards reaffirmed.
Also read: Tata Chemicals Approves ₹910 Crore Plant Expansions at Mithapur & Cuddalore
The following table summarises the elements disclosed after the inspection:
Category | Details |
Facility inspected | Lupin manufacturing unit, Goa |
Inspection authority | U.S. Food and Drug Administration |
Inspection dates | 10–21 November 2025 |
Final outcome | Form-483 issued |
Number of observations | Seven |
Next step | Company to submit written response |
Regulatory basis for disclosure | SEBI Listing Regulations, Regulation 30 |
A Form 483 is issued at the end of an FDA inspection when the investigators observe conditions that may represent violations of the Food, Drug, and Cosmetic Act and associated regulations.
Discovery made during an inspection at manufacturing site for Lupin has ramifications for its regulatory and operational status. Since the Goa location is part of Lupin’s broader supply chain, the seven findings may require corrective action, internal audits and possibly follow up inspections. Historically, Lupin has had issues flagged at their Goa facility during prior inspections when the process was conducted by the FDA.
Lupin made the disclosure pursuant to Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, which requires companies to report on a timely basis events that will impact the operations or performance of the company. The disclosure refers to the inspection period and finding, as well as the company's plan to respond.
While disclosures like this related to regulation are typical in the pharmaceutical industry, it further emphasizes the regulatory linkages between Indian manufacturing companies and those in the US.
Lupin share price stands at ₹2,033.90 per share on the BSE as of 21 Nov 2025 at 15:30 PM IST, up by 2.94%.
Disclaimer :
The information on this website is provided on "AS IS" basis. Bajaj Broking (BFSL) does not warrant the accuracy of the information given herein, either expressly or impliedly, for any particular purpose and expressly disclaims any warranties of merchantability or suitability for any particular purpose. While BFSL strives to ensure accuracy, it does not guarantee the completeness, reliability, or timeliness of the information. Users are advised to independently verify details and stay updated with any changes.
The information provided on this website is for general informational purposes only and is subject to change without prior notice. BFSL shall not be responsible for any consequences arising from reliance on the information provided herein and shall not be held responsible for all or any actions that may subsequently result in any loss, damage and or liability. Interest rates, fees, and charges etc., are revised from time to time, for the latest details please refer to our Pricing page.
Neither the information, nor any opinion contained in this website constitutes a solicitation or offer by BFSL or its affiliates to buy or sell any securities, futures, options or other financial instruments or provide any investment advice or service.
BFSL is acting as distributor for non-broking products/ services such as IPO, Mutual Fund, Insurance, PMS, and NPS. These are not Exchange Traded Products. For more details on risk factors, terms and conditions please read the sales brochure carefully before investing.
Investments in the securities market are subject to market risk, read all related documents carefully before investing. This content is for educational purposes only. Securities quoted are exemplary and not recommendatory.
For more disclaimer, check here : https://www.bajajbroking.in/disclaimer
Level up your stock market experience: Download the Bajaj Broking App for effortless investing and trading